DruSO-CU: Determinants of omalizumab drug survival in a long-term daily practice multicentre cohort of patients with Chronic Urticaria

This international, multi-center, retrospective cohort study aims to investigate effectiveness and safety of omalizumab in a large multicenter cohort of patients with CU by using drug survival analysis. Furthermore, this study aims to identify the determinants of drug survival.

Study type: multi-center daily practice cohort study

We intend to present the study results at international congresses (preferably EADV and/or EAACI) and to publish them in high impact peer-reviewed scientific journals. To become a coauthor, you need to participate in the project and contribute to sufficient patient recruitment (both quantity and quality), the interpretation of the study results and manuscript development. Participation is feasible for centers with CU patient populations treated with omalizumab of n > 100 and the guarantee that data can be provided for all patients, to avoid selection bias.

Deadline: finish patient inclusion; July 22nd, 2022 anticipated

Are you interested in participating in the study? Please visit our member’s areaor send an Email (h.rockmann@umcutrecht.nl) for additional information.

Are you familiar with Angioedema Centers of Reference and Excellence (ACARE)? In this episode, our host is joined by Dr Anete Grumach, to celebrate the recent successes of the ACARE network and discuss the future of this exciting initiative.

Link: www.medthority.com/csu-learning-zone/podcast-series/

Read more

Perhaps you have already heard about our Journal Club. Perhaps you also are or know a junior physician / PhD student who is interested in participating in the journal club. If so, please read on, and pass the information on

Read more

In this episode, our host is joined by Dr Caroline Mann, a urticariologist and sleep expert, who highlights the profound impact of sleep disturbance on quality of life in patients with urticaria and explains what can be done to address this common, but often overlooked aspect of the disease.

Link: https://www.medthority.com/csu-learning-zone/podcast-series/

Read more

Contact us

GA²LEN coordinating Office
c/o DGAKI
Robert-Koch-Platz 7
10115 Berlin, Germany

UCARE office
Laura Schwenner

info(at)ga2len-ucare.com